Skip to main content
SpringerLink
Log in

The Future of Management of Benign Prostatic Hyperplasia

  • Chapter
  • First Online:
The Big Prostate

  • 779 Accesses

Abstract

Much has changed over the past few decades in the management of benign prostatic enlargement. The most exciting aspect however, is in the future—there undoubtedly will arise medical and surgical options which boast vastly improved efficacy and safety compared with current treatments. From humble beginnings of blind incision, much has changed and will continue to do so—medical options including more specific subtypes of alpha blockers, and potential newer hormonal agents are around the corner. A variety of pro-apoptotic agents are also being investigated. Lasers, hydro-dissectors, steam ablation and high intensity ultrasound are just a few of the newer technologies emerging onto the market. Whilst various mechanical stents have been developed, many more will arise. Robotics and excitingly, nano-robotics, provide another frontier awaiting exploration. Regardless of your vantage point, new treatments will arise and we are tasked with the responsibility of applying them appropriately and safely, to facilitate the best improvement for our patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. World Report on Ageing and Health. Geneva: WHO; 2015.

    Google Scholar 

  2. Filson CP, Wei JT, Hollingsworth JM. Trends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2013;82(6):1386–92.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Cindolo L, Pirozzi L, Fanizza C, Romero M, Sountoulides P, Roehrborn CG, et al. Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men. Int Urol Nephrol. 2014;46(4):695–701.

    Article  CAS  PubMed  Google Scholar 

  4. Ingimarsson JP, Isaksson HJ, Sigbjarnarson HP, Gudmundsson J, Geirsson G. Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate. Scand J Urol. 2014;48(1):73–8.

    Article  CAS  PubMed  Google Scholar 

  5. Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004;64(6):1081–8.

    Article  PubMed  Google Scholar 

  6. Kojima Y, Sasaki S, Hayashi Y, Tsujimoto G, Kohri K. Subtypes of α1-adrenoceptors in BPH: future prospects for personalized medicine. Nat Clin Pract Urol. 2009;6(1):44–53.

    Article  CAS  PubMed  Google Scholar 

  7. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98.

    Article  CAS  PubMed  Google Scholar 

  8. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–31.

    Article  CAS  PubMed  Google Scholar 

  9. Shore N. NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2010;19(2):305–10.

    Article  CAS  PubMed  Google Scholar 

  10. Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst. 2007;99(5):376–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Denmeade SR, Egerdie B, Steinhoff G, Merchant R, Abi-Habib R, Pommerville P. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2011;59(5):747–54.

    Article  CAS  PubMed  Google Scholar 

  12. Adorini L, Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol. 2007;103(3–5):689–93.

    Article  CAS  PubMed  Google Scholar 

  13. Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E, et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2009;69(5):480–93.

    Article  CAS  PubMed  Google Scholar 

  14. Colli E, Rigatti P, Montorsi F, Artibani W, Petta S, Mondaini N, et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol. 2006;49(1):82–6.

    Article  CAS  PubMed  Google Scholar 

  15. Maclean C LF, Drewe J, Dzmitryieu AV, Gres A, Strockyi A, Dovger V, Ulys A, Cerniauskienè A, Geavlete P, Nikolovski M. Efficacy and safety of Teverelix LA, A new GNRH antagonist in patients with benign prostatic hyperplasia (BPH). Results from a phase II randomized, double-blind, placebo-controlled, multicentre, multinational study investigating two single injections of 60mg at 48 hours interval administered s.c. to treatment naive patients suffering from BPH. Eur Urol Suppl. 2007;6(2):109.

    Google Scholar 

  16. Debruyne F, Gres AA, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol. 2008;54(1):170–7.

    Article  CAS  PubMed  Google Scholar 

  17. Debruyne FMJ. The efficacy and safety of ozarelix, a novel GnRH antagonist, in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). J Urol. 2007;177(Suppl):512.

    Google Scholar 

  18. Norman BH, Dodge JA, Richardson TI, Borromeo PS, Lugar CW, Jones SA, et al. Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. J Med Chem. 2006;49(21):6155–7.

    Article  CAS  PubMed  Google Scholar 

  19. Munoz A, Somogyi GT, Boone TB, Ford AP, Smith CP. Modulation of bladder afferent signals in normal and spinal cord-injured rats by purinergic P2X3 and P2X2/3 receptors. BJU Int. 2012;110(8 Pt B):E409–14.

    Google Scholar 

  20. Inoue S, Saito M, Takenaka A. Hydroxyfasudil ameliorates bladder dysfunction in male spontaneously hypertensive rats. Urology. 2012;79(5):1186e9–14.

    Google Scholar 

  21. Schroder A, Tajimi M, Matsumoto H, Schroder C, Brands M, Andersson KE. Protective effect of an oral endothelin converting enzyme inhibitor on rat detrusor function after outlet obstruction. J Urol. 2004;172(3):1171–4.

    Article  PubMed  Google Scholar 

  22. Gilling PJ, Cass CB, Malcolm AR, Fraundorfer MR. Combination holmium and Nd:YAG laser ablation of the prostate: initial clinical experience. J Endourol. 1995;9(2):151–3.

    Article  CAS  PubMed  Google Scholar 

  23. Chilton CP, Mundy IP, Wiseman O. Results of holmium laser resection of the prostate for benign prostatic hyperplasia. J Endourol. 2000;14(6):533–4.

    Article  CAS  PubMed  Google Scholar 

  24. Robert G, Cornu JN, Fourmarier M, Saussine C, Descazeaud A, Azzouzi AR, et al. Multicentre prospective evaluation of the learning curve of holmium laser enucleation of the prostate (HoLEP). BJU Int. 2016;117(3):495–9.

    Article  PubMed  Google Scholar 

  25. Kuo RL, Kim SC, Lingeman JE, Paterson RF, Watkins SL, Simmons GR, et al. Holmium laser enucleation of prostate (HoLEP): the Methodist Hospital experience with greater than 75 gram enucleations. J Urol. 2003;170(1):149–52.

    Article  PubMed  Google Scholar 

  26. Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol. 2015;67(6):1066–96.

    Article  PubMed  Google Scholar 

  27. Gilling P, Reuther R, Kahokehr A, Fraundorfer M. Aquablation—image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int. 2016;117(6):923–9.

    Article  CAS  PubMed  Google Scholar 

  28. Dixon CCE, Pacik D. PD26-09 transurethral water vapor therapy for BPH; 1-year clinical results of the first-in-man and Rezum I clinical trials using the Rezum system. J Urol. 2014;191(4):e762.

    Article  Google Scholar 

  29. McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016;195(5):1529–38.

    Article  PubMed  Google Scholar 

  30. Wagrell LTM. Transurethral convective water vapor ablation therapy for BPH; a single center’s experience using the Rezum system in an office-based setting. J Urol. 2014;191(4s):e762.

    Article  Google Scholar 

  31. Roberts WW, Hall TL, Ives K, Wolf JS Jr, Fowlkes JB, Cain CA. Pulsed cavitational ultrasound: a noninvasive technology for controlled tissue ablation (histotripsy) in the rabbit kidney. J Urol. 2006;175(2):734–8.

    Article  PubMed  Google Scholar 

  32. Lake AM, Hall TL, Kieran K, Fowlkes JB, Cain CA, Roberts WW. Histotripsy: minimally invasive technology for prostatic tissue ablation in an in vivo canine model. Urology. 2008;72(3):682–6.

    Article  PubMed  Google Scholar 

  33. Madersbacher S, Kratzik C, Susani M, Marberger M. Tissue ablation in benign prostatic hyperplasia with high intensity focused ultrasound. J Urol. 1994;152(6 Pt 1):1956–60. discussion 60-1

    Article  CAS  PubMed  Google Scholar 

  34. Sullivan L, Casey RW, Pommerville PJ, Marich KW. Canadian experience with high intensity focused ultrasound for the treatment of BPH. Can J Urol. 1999;6(3):799–805.

    PubMed  Google Scholar 

  35. Madersbacher S, Schatzl G, Djavan B, Stulnig T, Marberger M. Long-term outcome of transrectal high- intensity focused ultrasound therapy for benign prostatic hyperplasia. Eur Urol. 2000;37(6):687–94.

    Article  CAS  PubMed  Google Scholar 

  36. Masood S, Djaladat H, Kouriefs C, Keen M, Palmer JH. The 12-year outcome analysis of an endourethral wallstent for treating benign prostatic hyperplasia. BJU Int. 2004;94(9):1271–4.

    Article  PubMed  Google Scholar 

  37. Kotsar A, Isotalo T, Juuti H, Mikkonen J, Leppiniemi J, Hanninen V, et al. Biodegradable braided poly(lactic-co-glycolic acid) urethral stent combined with dutasteride in the treatment of acute urinary retention due to benign prostatic enlargement: a pilot study. BJU Int. 2009;103(5):626–9.

    Article  PubMed  Google Scholar 

  38. Perera M, Roberts MJ, Doi SA, Bolton D. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol. 2015;67(4):704–13.

    Article  PubMed  Google Scholar 

  39. Mali S. Nanorobots: changing face of healthcare system. J Biomed Eng. 2014;1(3):1012.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Guy’s and St Thomas’ NHS Trust, London, UK

    Gideon Adam Blecher, Rick Leslie Catterwell & Ben Challacombe

  2. King’s College London, London, UK

    Ben Challacombe

Authors
  1. Gideon Adam Blecher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rick Leslie Catterwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ben Challacombe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gideon Adam Blecher .

Editor information

Editors and Affiliations

  1. University College London & University College London Hospital, London, United Kingdom

    Veeru Kasivisvanathan

  2. Guy’s and St Thomas’s Hospitals NHS Foundation Trust, London, United Kingdom

    Ben Challacombe

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Blecher, G.A., Catterwell, R.L., Challacombe, B. (2018). The Future of Management of Benign Prostatic Hyperplasia. In: Kasivisvanathan, V., Challacombe, B. (eds) The Big Prostate. Springer, Cham. https://doi.org/10.1007/978-3-319-64704-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64704-3_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64703-6

  • Online ISBN: 978-3-319-64704-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation